Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (NFKBIA) mRNA (NFKBIA mRNA)

NFKBIA mRNA encodes the IκBα protein, which serves as the primary endogenous inhibitor of the NF-κB transcription factor complex [1]. In its basal state, the IκBα protein binds to NF-κB dimers in the cytoplasm, masking their nuclear localization signals and preventing the transcription of genes involved in inflammation and cell survival [2]. Upon cellular stimulation by pro-inflammatory cytokines or pathogens, IκBα undergoes rapid phosphorylation and proteasomal degradation, releasing NF-κB to enter the nucleus [1]. Genetic alterations or low expression of NFKBIA mRNA are frequently observed in various malignancies, such as glioblastoma and Hodgkin lymphoma, leading to uncontrolled NF-κB activity and tumor progression [3]. Therapeutic targeting of NFKBIA mRNA is an emerging field, primarily utilizing mRNA replacement strategies to restore IκBα levels in cells where the gene is deleted or silenced [4]. By reintroducing functional NFKBIA mRNA, researchers aim to re-establish the inhibitory control over NF-κB, thereby inducing apoptosis in cancer cells and reducing chronic inflammation [5]. This approach differs from traditional small-molecule inhibitors that target upstream kinases or the proteasome, offering a more direct method to re-establish the natural inhibitory brake on the pathway [4]. Challenges in this therapeutic area include the efficient delivery of mRNA to target tissues and avoiding the activation of the innate immune system by the synthetic RNA molecules [5]. Sources: [1] UniProt P25963; [2] NCBI Gene ID 4792; [3] Bredel et al., NEJM (2011), PMID: 21177520; [4] Sahin et al., Nature Reviews Drug Discovery (2014); [5] Weng et al., Frontiers in Immunology (2021).

Other names

IkappaB-alpha mRNAIKBA mRNAMAD-3 mRNANF-kappa-B inhibitor alpha mRNAMajor histocompatibility complex enhancer-binding protein MAD3 mRNA

mRNA replacement therapy to restore IκBα protein levels, which subsequently sequesters NF-κB in the cytoplasm to inhibit its transcriptional activity.